Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04468282
Other study ID # ORP-VGB-I-a
Secondary ID 2017-000038-67
Status Completed
Phase Phase 1
First received
Last updated
Start date April 4, 2017
Est. completion date August 8, 2017

Study information

Verified date July 2020
Source Orphelia Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Methodology:

The study was an open label, randomized, crossover, 2 periods study in 20 healthy male/female volunteers. Subjects received 500 mg of the new formulation of soluble tablets vigabatrin or Sabril, as single oral administration in 2 different study periods depending on the randomization, with a 7-days wash out period between administrations


Description:

Objectives:

Primary objective:

Evaluate bioequivalence between a new paediatric formulation of vigabatrin (VGB-ST) and Sabril granules for oral administration.

Secondary objective:

- Define pharmacokinetic parameters of the new paediatric formulation soluble tablets of vigabatrin (VGB-ST)

- Assess the safety of the new formulation of soluble tablets VGB-ST versus Sabril


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 8, 2017
Est. primary completion date August 8, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Healthy male and female subject, aged between 18 and 50 years inclusive;

2. Females of childbearing potential/Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices, diaphragm, condoms or abstinence) for the duration of the trial and for 1 month after the last study drug administration; Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhoea duration at least 12 months);

3. Non breast-feeding female and negative pregnancy test at screening baseline;

4. Non-smoker subject or smoker of not more than 5 cigarettes per day;

5. Body Mass Index (BMI) between 18,5 and 25 kg/m2 inclusive;

6. Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination);

7. Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position

8. Normal ECG recording on a 12-lead ECG at the screening visit

9. Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests, urinalysis). Individual values out of the normal range could be accepted if judged clinically non relevant by the Investigator;

10. Normal dietary habits;

11. Signing a written informed consent prior to selection;

12. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.

Exclusion Criteria:

1. Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic, infectious disease or psychiatric disorders;

2. Frequent headaches and / or migraine, recurrent nausea and / or vomiting;

3. History of abnormal vision (e.g. reduced visual field, retinopathy, etc…);

4. Abnormal visual field recorded during the inclusion period;

5. Evidence of any clinically significant acute or chronic disease;

6. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position;

7. Surgery or blood donation (including in the frame of a clinical trial) within 2 months before administration;

8. General anaesthesia within 3 months before administration;

9. Presence or history of drug hypersensitivity, asthma or allergic disease diagnosed and treated by a physician;

10. Inability to abstain from intensive muscular effort;

11. No possibility of contact in case of emergency;

12. Any drug intake (except paracetamol or contraception) during the last month prior to the first administration;

13. History or presence of drug or alcohol abuse (alcohol consumption > 40 grams / day);

14. Excessive consumption of beverages containing xanthine bases (> 4 cups or glasses / day);

15. Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody (not including HSV), or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests;

16. Positive results of screening for drugs of abuse;

17. Subject who, in the judgment of the Investigator, was likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;

18. Exclusion period of a previous study;

19. Administrative or legal supervision;

20. Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VGB-ST
Single oral administration of 500 mg VGB-ST

Locations

Country Name City State
France Eurofins Optimed Gières

Sponsors (1)

Lead Sponsor Collaborator
Orphelia Pharma

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary pharmacokinetic parameters (Bioequivalence) The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: Cmax day 1 or 2
Primary Primary pharmacokinetic parameters (Bioequivalence) The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: AUC0-t day 1 or 2
Secondary Secondary pharmacokinetic parameters The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: AUC0-inf day 1 or 2
Secondary Secondary pharmacokinetic parameters The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: tmax day 1 or 2
Secondary Secondary pharmacokinetic parameters The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: ? day 1 or 2
Secondary Secondary pharmacokinetic parameters The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: t1/2 day 1 or 2
Secondary Secondary pharmacokinetic parameters The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: residual area day 1 or 2
See also
  Status Clinical Trial Phase
Completed NCT04467346 - Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules Phase 1
Completed NCT00807118 - Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect Phase 1
Withdrawn NCT01405170 - A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions Phase 1
Completed NCT04885660 - Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects Phase 1
Completed NCT05786339 - Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects Phase 1
Completed NCT00709189 - Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women. Phase 1
Completed NCT00685165 - Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets Phase 1
Completed NCT00658541 - Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets Phase 1
Completed NCT00997789 - Bioequivalence of Rebamipide in Korean N/A
Completed NCT00684762 - Fasted Bioavailability Study of Cilostazol Tablets, 100 mg Phase 1
Recruiting NCT04814589 - Bioequivalence of Ezetimibe Tablets in Healthy Subjects Phase 1
Completed NCT03631316 - Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir N/A
Recruiting NCT04438720 - Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects Phase 1
Completed NCT01359163 - A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects Phase 1
Completed NCT00650221 - Fasting Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects Phase 1
Completed NCT00648544 - Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects Phase 1
Completed NCT05225974 - A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects Phase 1
Withdrawn NCT01405131 - A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Phase 1
Withdrawn NCT01405157 - A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions Phase 1
Completed NCT05282940 - Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product Phase 1